Skip to main content

Table 3 Serious adverse events

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Patient PIN

Event

Duration of experimental therapy

Attribution

178

Pneumothorax due to central line insertion. Death

5 days

Not related

384

Malignancy. Death

139 days

Probably not related

663

Sudden death

11 days

Not related

459

Severe pneumonia with respiratory failure

6 months (17 days after the last dose of imatinib)

Unlikely related